Versant Vantage I, L.P.'s Net Worth
Estimate Recalculated Nov 1, 2024 11:31AM EST
Who is Versant Vantage I, L.P.
Versant Vantage I, L.P. does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include Repare Therapeutics Inc., Monte Rosa Therapeutics, Inc., Oyster Point Pharma, Inc., Aligos Therapeutics, Inc., Pandion Therapeutics Holdco LLC, Passage BIO, Inc., Black Diamond Therapeutics, Inc., RayzeBio, Inc., Aprea Therapeutics, Inc., and Contineum Therapeutics, Inc..
SEC CIK
Versant Vantage I, L.P.'s CIK is 0001765253
Past Insider Trading and Trends
2019 was Versant Vantage I, L.P.'s most active year for acquiring shares with 1 total transactions. Versant Vantage I, L.P.'s most active month to acquire stocks was the month of September. 2021 was Versant Vantage I, L.P.'s most active year for disposing of shares, totalling 5 transactions. Versant Vantage I, L.P.'s most active month to dispose stocks was the month of December. 2019 saw Versant Vantage I, L.P. paying a total of $4,999,995.00 for 333,333 shares, this is the most they've acquired in one year. In 2021 Versant Vantage I, L.P. cashed out on 377,071 shares for a total of $0.00, their largest year based on trade value.
Attention insiders:Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
